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All important drug interactions, with the possible exception of idiosyncratic or al-
lergic reactions, have a pharmacokinetic or pharmacodynamic basis, or both (1). A study
of the mechanisms of drug interactions is of much value in selecting proper drug combi-
nations in order to provide rational therapy, especially for drugs that have a narrow
margin of safety and where drugs are used for a prolonged period of time. Most re-
cently, pharmacogenetics has linked drug interaction outcomes to variations in genes
encoding cytochrome P450 (CYP) enzymes (2) and transporter genes.
Statins (or HMG-CoA reductase inhibitors) represent a class of drugs used to lower
cholesterol levels by inhibiting the enzyme HMG-CoA reductase, which plays a central
role in the production of cholesterol in the liver. As of 2010, a number of statins have
been on the market: atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosu-
vastatin, and simvastatin (3).
Statins are associated with two uncommon, but important, adverse effects, asympto-
matic elevation in liver enzyme activity and myopathy. In 2001, cerivastatin was with-
drawn from the market worldwide because of an unacceptably high incidence of serious
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myopathy (creatine kinase >10 times the upper limit of normal) and rhabdomyolysis.
Although rare, myopathy and rhabdomyolysis remain a serious concern with other
statins as well (4, 5). Myopathy is most likely to occur when statins are administered with
other drugs or chemicals that are themselves myotoxic or that can elevate statin concen-
trations to a toxic range. The mechanism of rhabdomyolysis caused by statins is poorly
defined, but its occurrence increases with the drug dose/concentration (6). Therefore,
the risk of adverse effects increases when drugs that can exclusively cause rhabdomyo-
lysis are used concomitantly with other drugs that can increase their effects via interac-
tions.
At the pharmacodynamic level (i.e., at their site of action), statins are not prone to
interfere with other drugs. However, at the pharmacokinetic level (i.e., absorption, dis-
tribution, metabolism and excretion of a given drug), the available statins show notable
differences, including half-life, systemic exposure, maximum plasma concentration
(Cmax), bioavailability, protein binding, lipophilicity, metabolism, presence of active me-
tabolites, and excretion routes (7, 8). Pharmacokinetic differences among statins are pre-
sented in Table I (9).
STATINS AS SUBSTRATES FOR CYP ENZYMES AND DRUG TRANSPORTERS
Statins are substrates for multiple membrane transporters including organic anion-
transporting polypeptide (OATP1B1), breast cancer resistance protein (BCRP), and
P-glycoprotein 1 (permeability glycoprotein, abbreviated as P-gp or Pgp) also known as
multidrug resistance protein 1 (MDR1) and several cytochrome P450 (CYP) enzymes (in-
cluding CYP3A4, CYP2C8, CYP2C19, and CYP2C9) (10). Drug transporters play an im-
portant role in statin disposition. Influx transporters, such as OATP1B1, and efflux trans-
porters, such as multidrug resistance-associated protein 2 (MRP2), work together within
the liver transcellular transport.
The significance of OATP1B1 has recently been emphasized by its inclusion among
the seven transporters of considerable importance for drug disposition (11, 12).
OATP1B1 transporter has been reported to be involved in the hepatic uptake of statins
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Atorvastatin 2–3 27–66 12 Yes 80–90 CYP3A4 15–30
Fluvastatin 0.5–1 448 19–29 Yes > 90 CYP2C9 0.5–2.3
Lovastatin 2–4 10–20 5 Yes > 95 CYP3A4 1.3–2.8
Pravastatin 0.9–1.6 45–55 18 No 43–55 Sulphation 1.3–2.8




Simvastatin 1.3–2.4 10–34 5 Yes 94–98 CYP3A4 2–3
and thus to reduce drug loss in systemic circulation and the development of side effects
such as muscle myopathy. The gene encoding OATP1B1 is SLCO1B1. Clinical studies
identified SLCO1B1 variants as a risk factor for statin-induced adverse events (13–15).
Genetic polymorhisms in SLCO1B1 affect the pharmacokinetics of statins. T521C
and A388G are functional variants associated with Val174Ala and Asn130Asp. Two com-
mon full (SNPs) in SLCO1B1 have been associated with increased levels of pravastatin
(16, 17). Also, a polymorphism in the 5’-untranslated region of SLCO1B1 affected the
AUC and Cmax of pravastatin (18). A recent study examining the relationship between an
OATP1B1 variant and atorvastatin and pravastatin-induced rhabdomyolysis found that
the OATP-C*15 mutant allele was significantly higher in patients who experienced
statin-induced myopathy, suggesting the significance of OATP1B1 down-regulation to
statin exposure (19, 20). Thus, recent evidence demonstrated a significant difference in
statin therapy outcomes, which could be, at least partially, attributed to the genetic vari-
ations of membrane transporters.
The liver biotransforms all statins, which accounts for their overall low systemic
bioavailability. With the exception of pravastatin, which is transformed enzymatically in
the liver cytosol, all statins undergo extensive microsomal metabolism by the cyto-
chrome P450 (CYP) isoenzyme systems. Involvement of individual CYP enzymes or
transporters in their disposition varies from statin to statin. The CYP3A4 isoenzyme is
responsible for the metabolism of lovastatin, simvastatin, and atorvastatin. Fluvastatin
is primarily metabolized by the CYP2C9 enzyme, with CYP3A4 and CYP2C8 contribut-
ing to a lesser extent (7). Rosuvastatin is not extensively metabolized, but has some in-
teraction with the CYP2C9 enzyme (8).
Induction or inhibition of CYP450 isoenzymes is an important cause of drug interac-
tions. Competitive inhibition between drugs at the enzymatic level is common and may
serve to alter the disposition of statins, leading to increased plasma levels and greater risk of
adverse events. On the basis of the above mentioned facts, it can be concluded that in pa-
tients requiring concurrent use of statins and CYP3A4 inhibitors, pravastatin or flu-
vastatin would be reasonable choices to minimize potential drug-drug interactions,
whereas atorvastatin seems to carry a moderate risk and should be used with caution.
Simvastatin and lovastatin carry the highest risk of drug interactions and should be
avoided in patients taking concomitant CYP3A4 inhibitors (21).
Therefore, statin plasma levels may increase after CYP3A4 inhibitor treatments (10,
22) or get decreased by CYP3A4 inducers (23).
Major statin-drug interactions
Amiodarone. – Amiodarone is an antiarrhythmic agent used for various types of car-
diac dysrhythmias and is a potent inhibitor of CYP3A4 (24, 25). This inhibition is pri-
marily due to its active metabolite, desethylamiodarone, which noncompetitively inhib-
its CYP3A4 (26) and drugs metabolized by it, including statins. In previously reported
cases, amiodarone was found to increase rhabdomyolysis risk when taken with simva-
statin (21, 27–29). Simvastatin-related adverse event reports with concomitant amioda-
rone use were 1 %. The adverse event reports with atorvastatin and pravastatin use were
0.7 and 0.4 %, respectively, when combined with amiodarone, of which about 77 % were
due to muscle toxicity (30). A study (31) revealed that 79 (85.9 %) patients on a combina-
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tion of amiodarone and simvastatin at doses greater than 20 mg per day had at least one
additional risk factor for myopathy or rhabdomyolysis during the history of combina-
tion therapy. Amiodarone-lovastatin co-administration also needs precaution because
lovastatin is metabolized by CYP3A4 as well.
Antibiotics. – The macrolide antibiotics erythromycin, clarithromycin, troleandomy-
cin, and telithromycin have been mentioned as potential interacting agents with statins
in standard drug references (32) because they are cleared through the same metabolic
pathway, regulated by CYP3A4. Even though the newer macrolide azithromycin has not
been suggested to cause clinically significant interactions with agents metabolized through
the cytochrome P450 enzyme system (33–35), there are certain case reports suggesting an
interaction between azithromycin and statins (36–38).
Even though the major mechanism underlying drug interactions with macrolides is
believed to be inhibition of the major drug metabolizing enzyme CYP3A4 in small intes-
tine and liver, published data indicate that certain macrolides are also inhibitors of the
apically/luminally localized drug efflux pump P-gp (39–41). By inhibiting P-gp function
they increase drug absorption from the gut lumen and decrease biliary elimination and
renal secretion of concomitantly administered drugs (42). This in turn leads to increased
drug concentrations and drug toxicity. It has been demonstrated that the macrolides
clarithromycin and erythromycin significantly increase pravastatin plasma concentra-
tions (43). Because pravastatin is not metabolized by cytochrome P450 enzymes, uptake
transporters may account for this drug-drug interaction. Despite the increasingly recog-
nized role of full OATP uptake transporters in drug disposition, their role has not been
systematically studied. However, macrolides are inhibitors of the uptake of concomi-
tantly administered drugs mediated by OATPs and thereby provide an additional mech-
anism of macrolide-induced drug interactions (44). Hirano et al. (45) recently demon-
strated that both clarithromycin and erythromycin were inhibitors of the uptake of
pitavastatin, an established OATP1B1 substrate.
Among fluoroquinoline antibiotics, fluroquinolone ciprofloxacin is partially metab-
olized in liver. It is a strong inhibitor of CYP1A2 and a weak inhibitor of CYP3A4. Ci-
profloxacin-simvastatin interaction has been reported to the Medicines and Healthcare
Products Regulatory Agency (MHRA), UK (46).
Azole antifungals. – Co-administration of simvastatin with itraconazole, an antifungal
agent, can result in rhabdomyolysis (47). Itraconazole, even at a small dosage of 100 mg
daily, greatly elevated plasma concentrations of lovastatin and its active metabolite, lo-
vastatin acid. Therefore, lovastatin should not be used concomitantly with itraconazole
and other potent CYP3A4 inhibitors, or the dosage of lovastatin should be greatly re-
duced while using a CYP3A4 inhibitor. In contrast, fluvastatin concentration was not
significantly increased by itraconazole, indicating that fluvastatin has much less poten-
tial than lovastatin for clinically significant interactions with itraconazole (48). Interac-
tions between ketokonazole and simvastatin (49–51) or lovastatin (52) have also been de-
scribed. Rhabdomyolysis as a consequence of fluconazole interaction with statins has
been reported as well (53–56).
Calcium channel antagonists. – Calcium channel antagonists are weak inhibitors of
CYP3A4. They increase the plasma concentration of statins (57, 58). Both benidipine and
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azelnidipine have been shown to inhibit metabolism in vitro in a concentration-depend-
ent manner (59).
Cases of rhabdomyolysis have been reported with the association of diltiazem with
atorvastatin or simvastatin (60, 61), suggesting some need for caution in using these
agents simultaneously.
Mibefradil, at therapeutically relevant concentrations, strongly suppressed the me-
tabolism of simvastatin, lovastatin, atorvastatin and cerivastatin in human liver micro-
somes through its inhibitory effects on CYP3A4/5, while the effects of mibefradil on flu-
vastatin, a substrate for CYP2C8/9, were minimal in this system (62).
Administration of nifedipine may elicit a detrimental efffect on statin therapy, re-
sulting in a worsening of cardiac performance. This may suggest another mechanism of
drug-drug interaction than the one based on CYP3A4 inhibition (63).
The effects of verapamil on the pharmacokinetics of simvastatin and lovastatin have
been investigated in healthy volunteers. Verapamil caused a 4.6-fold increase in the
mean area under the concentration-time curve of simvastatin (64).
Citrus juices. – Given that simvastatin, lovastatin and atorvastatin are metabolized
by CYP3A4, they are affected by the interaction with grapefruit juice, which has been re-
ported to inhibit CYP3A4. However, a number of studies focus on other interaction
mechanisms besides that of CYP 3A4. Grapefruit juice also inhibits P-gp, a transporter
that carries drugs from the enterocyte back to the gut lumen, resulting in further increa-
se in the fraction of the drug absorbed. Grapefruit juice is also capable to inhibit human
organic anion-transporting polypeptide B (OATP-B) in vitro (65). This inhibition decrea-
ses the intestinal uptake and therefore the oral bioavailability of the drug, which is the
opposite effect to that of CYP3A4 inhibition. Nevertheless, the contribution to the bio-
availability of statins affected by P-gp and OATP-B inhibition remains unclear. In 2007,
esterase inhibition by grapefruit juice was described as a new drug interaction (66).
Remarkably, even one glass of grapefruit juice taken daily considerably increases
plasma concentrations of simvastatin and simvastatin acid. Grapefruit juice may increase
both the cholesterol-lowering effect and the risk of adverse effects of simvastatin (67, 68).
Lilja et al. (69) demonstrated that grapefruit juice significantly increases serum con-
centrations of atorvastatin, both in its acid and lactone forms. Nevertheless, this juice
does not appear to have any effect on the pharmacokinetics of pravastatin due to its
hydrosolubility (70). A Japanese study also confirmed the interaction of grapefruit juice
with atorvastatin but not with pravastatin (71).
Orange juice increases pravastatin AUC, without affecting its excretion rate. This ef-
fect could be related to higher intestinal absorption of the drug, mediated by the orange
juice, but the mechanism is not clear and further studies are necessary. Orange juice
does not alter simvastatin pharmacokinetics (72). One report highlights the possible in-
teraction between rosuvastatin and pomegranate juice that caused rhabdomyolysis in
one patient (73).
Immunosuppresants. – Previous clinical studies have shown that plasma concentra-
tion of pitavastatin was increased by cyclosporine A (74). It has been demonstrated that
OATP could be a major determinant of causing clinical drug-drug interactions between
cerivastatin and cyclosporine as well (20, 75). The area under the curve of the OATP1B1
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substrate rosuvastatin was increased 7.1 times when it was co-administered with the
OATP1B1 inhibitor cyclosporine A. In vitro models suggested that the observed increase
in the AUC was related to the inhibition of OATP1B1 (12, 76).
There are case reports of developing rhabdomyolysis due to concomitant use of
simvastatin and cyclosporine (77–79). Fluvastatin, which is primarily metabolized by
CYP2C9, and pravastatin and rosuvastatin, which are eliminated by other metabolic routes,
are less subject to this interaction than other statins. However, a 5- to 23-fold increase in
pravastatin bioavailability has been reported in the presence of cyclosporine A. This
suggests that cyclosporine may interact with statins via mechanisms not limited to
CYP3A4 inhibition. On the other hand, fluvastatin shows a far milder interaction with
cyclosporine (7, 80).
An interaction between erlotinib and simvastatin leading to rhabdomyolysis has
been reported (81). The results of a study by Katsakiori (82) empower the belief that
tacrolimus and concomitantly administrated statin do not interact in terms of efficacy,
efficiency and side-effect development. No significant clinical interaction was observed
even for atorvastatin and simvastatin.
Nefazodone. – Concurrent administration of nefazodone, an antidepressant, and an
HMG-CoA reductase inhibitor metabolized by CYP3A4 may result in elevated statin le-
vels. Elevated levels of the HMG CoA reductase inhibitor may result in rhabdomyolysis
(83, 84). In a single-dose study, the administration of simvastatin (40 mg) or atorvastatin
(40 mg) following six days of nefazodone (200 mg twice daily) resulted in a 20-fold in-
crease in simvastatin and simvastatin acid levels and a 3- to 4-fold increase in atorva-
statin and atorvastatin lactone levels (85).
Protease inhibitors. – A significant potential exists for drug-drug interactions with the
combination of protease inhibitors and statins via competitive and reversible inhibition
of CYP3A4. Certain agents of the HIV protease inhibitor class can induce elevations in
serum lipids (86, 87).
Nelfinavir, 1250 mg twice daily taken with either atorvastatin (10 mg once daily) or
simvastatin (20 mg once daily), caused a 74 % increase in the AUC of atorvastatin and
505 % increase in the AUC of simvastatin (88).
Co-administration of lopinavir-ritonavir with atorvastatin (20 mg once daily) caus-
ed a 5.8-fold increase in atorvastatin AUC, whereas lopinavir-ritonavir given with pra-
vastatin (20 mg once daily) had relatively little effect on pravastatin (89).
A 40 mg dose of either simvastatin, atorvastatin or pravastatin was administered
with the dual protease inhibitor regimen of saquinavir soft gel capsule 400 mg twice
daily and ritonavir 400 mg twice daily. The combination had a dramatic impact on sim-
vastatin, with the area under the curve of simvastatin acid, the active form of simvas-
tatin, increasing by 3000 %. The AUC of total active atorvastatin (the sum of atorvastatin
plus two active metabolites) increased by 79 % (90).
Surprisingly, the AUC of pravastatin decreased by 50 % in the presence of saquina-
vir plus ritonavir. In a separate study, nelfinavir given concomitantly with pravastatin
caused a 47 % decrease in the AUC of pravastatin (91).
A clinically relevant increase in rosuvastatin and atorvastatin concentrations during
co-administration of tipranavir co-administered with low-dose ritonavir (tipranavir/r)
282
A. Causevic-Ramosevac and S. Semiz: Drug interactions with statins, Acta Pharm. 63 (2013) 277–293.
500 mg/200 mg twice daily was reported. Based on these results, a low initial dose of
rosuvastatin (5 mg) and atorvastatin (10 mg) is recommended when combined with ti-
pranavir/r, with careful clinical monitoring of rosuvastatin- or atorvastatin-related ad-
verse effects, such as myopathy (92).
Warfarin. – Although an interaction study has demonstrated a lack of interaction be-
tween atorvastatin and warfarin after 15 days of combination therapy (93), at least three
studies have shown consistent increases in warfarin effect and/or dose reductions dur-
ing concurrent use of simvastatin (94–96). A case of fatal cerebral hemorrhage following
a switch from atorvastatin to simvastatin in a patient taking warfarin has been reported
(97). Three reports described interactions between warfarin and lovastatin in which
prothrombin times were increased (98–100). In addition, two reports (case series) of pos-
sible interactions with fluvastatin and warfarin cited three cases each (101, 102).
Phenytoin. – Phenytoin, another inducer of CYP3A4, can alter the lipid-lowering ef-
ficacy of both atorvastatin and simvastatin (103, 104).
Rifampicin. – It has been shown that rifampicin greatly decreases plasma concentra-
tions of simvastatin (105). Rifampicin also caused a statistically significant decrease in
the plasma concentration of pravastatin given as a single oral dose to healthy subjects.
However, the effect of rifampicin varied greatly between subjects. The mean rifampicin-
-induced decrease in pravastatin concentration was considerably smaller than that ob-
served previously for simvastatin (106).
St. John’s wort. – The herbal supplement St. John’s wort appears to decrease plasma
levels of simvastatin but not those of pravastatin (107, 108).
Clopidogrel. – Previous studies suggested that atorvastatin, but not pravastatin, in vi-
tro decreased the inhibitory effect of clopidogrel on platelet aggregation (109).
A population-based cohort study investigated interactions between CYP3A4-metab-
olized statins and clopidogrel (110). Compared to the control group (treated with
non-CYP3A4-metabolized statins), co-prescription of CYP3A4-metabolized statins was
associated with an increase in adverse outcomes, though not statistically significant.
This controversy remains unresolved, since subsequent studies investigating the effects
of atorvastatin and/or simvastatin on anti-platelet effects of clopidogrel failed to con-
firm the initial findings (110–116).
Other authors (117) have shown that at clopidogrel concentrations > 10 mmol L–1,
CYP3A4 is mainly responsible for clopidogrel biotransformation, whereas CYP2C19
contributes only at clopidogrel concentrations ≤ 10 mmol L–1, which may explain the
conflicting results of in vitro and in vivo investigations regarding drug interactions with
clopidogrel.
Fibrates. – The absence of a significant pharmacokinetic interaction between feno-
fibrate and atorvastatin is consistent with recent results showing no difference in the sa-
fety profile between atorvastatin used as monotherapy or in combination with fenofibric
acid. Together, these data suggest that atorvastatin-fenofibrate combination therapy is
unlikely to pose a risk to patients (118).
Reports on the in vitro inhibitory potential of gemfibrozil demonstrated that this li-
pid-lowering drug is a more potent inhibitor of CYP2C9 than of CYP2C8 (119-121).
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However, in the clinic, gemfibrozil is a more potent inhibitor of CYP2C8 than of
CYP2C9. Interaction between gemfibrozil and pravastatin could occur at the transport
protein level. Gemfibrozil increases the AUC of the open acid form of simvastatin, lova-
statin, pravastatin, and pitavastatin, but it does not affect the AUC of the lactone form of
simvastatin and lovastatin and reduces that of pitavastatin (122–126). Gemfibrozil seems
to have no effect on the plasma concentration of fluvastatin (127).
The limited effect of gemfibrozil on plasma concentrations of the open acid forms of
simvastatin and lovastatin can be explained by inhibition of lactone formation followed
by full (UGT)-mediated glucuronidation. The reduced AUC of the lactone form of pita-
vastatin may be also explained by the same mechanism (121).
In addition, the membrane transporter OATP1B1 may also be involved in the repor-
ted drug-drug interactions of gemfibrozil and a number of statins (10, 12). In the appro-
ved label of pravastatin, there is a statement on the risk of its co-administration with
cyclosporine. The approved label of simvastatin also bears a statement on the risk of
myopathy when it is co-administered with cyclosporine or gemfibrozil (both are
OATP1B1 inhibitors) (15).
Digoxin. – Digoxin may affect the pharmacokinetics of statins. Acute interactions
have been observed with simvastatin (128) and co-administration of atorvastatin 80 mg
per day and digoxin 0.25 mg per day for 20 days increased systemic exposure to digoxin
by inhibiting P-glycoprotein. However, administration of atorvastatin 10 mg per day
with digoxin did not affect the mean steady-state concentrations of digoxin (129). Rosu-
vastatin, but not fluvastatin, has been shown to be recognized by these drug transport-
ers (130, 131).
Major drug interactions with statins are presented in Table II.
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Table II. Major drug interactions with statins and the proposed interaction mechanism
Mechanism of interaction Drug/substance Reference




















Drug-drug interactions are identified as a leading cause of hospitalization and
death. However, it is unlikely that all clinically possible interactions can be predicted.
Conditions under which drug-drug interactions occur, their clinical relevance, and me-
chanisms causing them, therefore represent a highly active field in pharmacological re-
search. Statins have proven to be safe in numerous clinical trials. However, studies have
shown that they can interact with other co-administered medicines. Principal mecha-
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Grapefruit juice

















Induction of CYP3A4 Phenytoin 103, 104
Rifampicin 105, 106
St. John’s wort 107, 108
Inhibition of CYP2C8 and CYP2C9 Gemfibrozil 118–127
Inhibition of CYP2C19 Clopidogrel 117







Inhibition of OATP1B1 Citrus Juice
Grapefruit juice
Orange juice, pomegranate juice
65
Cyclosprine 12, 20, 74–76
Gemfibrozil 10, 12, 15
nisms of drug-drug interactions are a direct inhibition of enzymatic activity, which may
be reversible or irreversible in nature, and induction or repression of enzyme gene ex-
pression. Furthermore, genetic variations of drug transporters appear to have an addi-
tional role in the fate of statins in human body. The different pharmacokinetic profiles of
different statins should be carefully examined in order to understand the different spec-
tra of drug interactions. These interactions are important determinants of safety in pa-
tients with hypercholesterolemia, especially those requiring long-term therapy with
drugs that are well-known CYP3A4 inhibitors/inducers. Therefore, concern is warrant-
ed particularly when statins are used in the multidrug regimens due to the dose-depen-
dent toxicity and their propensity toward marked elevations in concentration if taken
with drugs that inhibit first-pass metabolism.
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